Skip to Main Content

Author Details

Reem Al-Daccak
INSERM UMRS, University Paris Cite
1990
77
30
Antoine Forget (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36483552The mechanisms underlying the immune control of Zika virus infection at the maternal-fetal interface.Front Immunol2022
32049348Extracellular vesicles from human cardiovascular progenitors trigger a reparative immune response in infarcted hearts.Cardiovasc Res2021
33808520Stem Cells-Derived Extracellular Vesicles: Potential Therapeutics for Wound Healing in Chronic Inflammatory Skin Diseases.Int J Mol Sci2021
34772433The impact of Mediterranean diet on coronary plaque vulnerability, microvascular function, inflammation and microbiome after an acute coronary syndrome: study protocol for the MEDIMACS randomized, controlled, mechanistic clinical trial.Trials2021
34368184Innate Immune Response to Viral Infections at the Maternal-Fetal Interface in Human Pregnancy.Front Med (Lausanne)2021
32528049Metabolic reprogramming by Zika virus provokes inflammation in human placenta.Nat Commun2020
30924311Extracellular Vesicles Released by Allogeneic Human Cardiac Stem/Progenitor Cells as Part of Their Therapeutic Benefit.Stem Cells Transl Med2019
30713534Editorial: Alloimmune Response From Regenerative Medicine.Front Immunol2019
31043590Beta1 integrin blockade overcomes doxorubicin resistance in human T-cell acute lymphoblastic leukemia.Cell Death Dis2019
29389360Transplantation of Human Embryonic Stem Cell-Derived Cardiovascular Progenitors for Severe Ischemic Left Ventricular Dysfunction.J Am Coll Cardiol2018
30077201Autologous white blood cell infusion for trauma, brain trauma, stroke and select immune dysfunction co-morbidities: A promising and timely proposal?Med Hypotheses2018
29921651Safety and Efficacy of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients With ST-Segment Elevation Myocardial Infarction and Left Ventricular Dysfunction.Circ Res2018
30420629Genotype specific pathogenicity of hepatitis E virus at the human maternal-fetal interface.Nat Commun2018
28533209Rationale and Design of a Clinical Trial to Evaluate the Safety and Efficacy of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction: The Randomized Multicenter Double-Blind Controlled CAREMI Trial (Cardiac Stem Cells in Patients With Acute Myocardial Infarction).Circ Res2017
28300217Corrigendum: Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells.Sci Rep2017
28117403Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells.Sci Rep2017
29052594Corrigendum: Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells.Sci Rep2017
29123530Human Cardiac-Derived Stem/Progenitor Cells Fine-Tune Monocyte-Derived Descendants Activities toward Cardiac Repair.Front Immunol2017
27462789IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.Oncotarget2016
27589729Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type.Int J Mol Sci2016
27759009ZIKA virus reveals broad tissue and cell tropism during the first trimester of pregnancy.Sci Rep2016
25446398Polymorphisms in oxidative stress-related genes are associated with nasopharyngeal carcinoma susceptibility.Immunobiology2015
26666685Natural cytotoxicity receptor splice variants orchestrate the distinct functions of human natural killer cell subtypes.Nat Commun2015
26206374Allogenic benefit in stem cell therapy: cardiac repair and regeneration.Tissue Antigens2015
24499734TGF-β-induced (TGFBI) protein in melanoma: a signature of high metastatic potential.J Invest Dermatol2014
25505957Post-traumatic stress disorder: revisiting adrenergics, glucocorticoids, immune system effects and homeostasis.Clin Transl Immunology2014
25213554Natural killer cell crosstalk with allogeneic human cardiac-derived stem/progenitor cells controls persistence.Cardiovasc Res2014
23243206Allogenicity of human cardiac stem/progenitor cells orchestrated by programmed death ligand 1.Circ Res2013
25095515Immunoregulation and allogenicity in cardiac stem cell regenerative therapy.Clin Transpl2013
23994587Soluble MICA-NKG2D interaction upregulates IFN-γ production by activated CD3-CD56+ NK cells: potential impact on chronic graft versus host disease.Hum Immunol2013
23403517Mass spectrometry reveals changes in MHC I antigen presentation after lentivector expression of a gene regulation system.Mol Ther Nucleic Acids2013
22457358α2β1 integrin promotes chemoresistance against doxorubicin in cancer cells through extracellular signal-regulated kinase (ERK).J Biol Chem2012
22789622Anti-HLA antibodies in regenerative medicine stem cell therapy.Hum Immunol2012
22454190Plasticity of melanoma cells induced by neural cell crest conditions and three-dimensional growth.Melanoma Res2012
21441454MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis.J Immunol2011
21526207Melanoma spheroids grown under neural crest cell conditions are highly plastic migratory/invasive tumor cells endowed with immunomodulator function.PLoS One2011
19574933Coexpression of major histocompatibility complex class II with chemokines and nuclear NFkappaB p50 in melanoma: a rational for their association with poor prognosis.Melanoma Res2009
20559977Immunogenicity and allogenicity: a challenge of stem cell therapy.J Cardiovasc Transl Res2009
17719638The context of HLA-DR/CD18 complex in the plasma membrane governs HLA-DR-derived signals in activated monocytes.Mol Immunol2008
18234961Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis.Mol Cancer Res2008
17304627Pathologic expression of MHC class II is driven by mitogen-activated protein kinases.Eur J Immunol2007
14734118MHC class II signaling in antigen-presenting cells.Curr Opin Immunol2004
15577315Class II transactivator (CIITA) isoform expression and activity in melanoma.Melanoma Res2004
15302575HLA-DR signaling inhibits Fas-mediated apoptosis in A375 melanoma cells.Exp Cell Res2004
12672059Signaling through HLA-DR induces PKC beta-dependent B cell death outside rafts.Eur J Immunol2003
11754003Involvement of zinc in the binding of Mycoplasma arthritidis-derived mitogen to the proximity of the HLA-DR binding groove regardless of histidine 81 of the beta chain.Eur J Immunol2002
12202398A CD18-dependent protein kinase C beta-mediated alternative cell death pathway of activated monocytes.Int Immunol2002
12209641MHC class II isotype-specific signaling complex on human B cells.Eur J Immunol2002
10556806CD40 associates with the MHC class II molecules on human B cells.Eur J Immunol1999
10363722Ligation of MHC class II molecules differentially upregulates TNF beta gene expression in B cell lines of different MHC class II haplotypes.Hum Immunol1999
  • 1 - 50 of 77

Recommended Authors

Ning Jiang
The University of Texas at Austin
Career Start Year 2000
Number of shared co-authors 0
Miriam Merad
The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Career Start Year 2000
Number of shared co-authors 0
Chance John Luckey
University of Virginia School of Medicine.
Career Start Year 1995
Number of shared co-authors 0
Ping Jin
Center for Cellular Engineering, National Institutes of Health Clinical Center
Career Start Year 1993
Number of shared co-authors 0
Claudia Giachino
University of Turin
Career Start Year 1991
Number of shared co-authors 0
Jonathan S Serody
The University of North Carolina School of Medicine
Career Start Year 1991
Number of shared co-authors 0
Volker Eckstein
Heidelberg University
Career Start Year 1990
Number of shared co-authors 0
Laura Santambrogio
Weill Cornell School of Medicine
Career Start Year 1988
Number of shared co-authors 1
Kaoru Saijo
Helen Wills Neuroscience Institute, University of California berkeley
Career Start Year 1988
Number of shared co-authors 0
Drake Laface
Merck & Co. Inc.
Career Start Year 1987
Number of shared co-authors 0
Maura Rossetti
University of California Los Angeles
Career Start Year 1986
Number of shared co-authors 0
Denis-Claude Roy
Universite de Montreal
Career Start Year 1985
Number of shared co-authors 1
Su M Metcalfe
University of Cambridge Clinical School, LIFNanoRx Ltd
Career Start Year 1984
Number of shared co-authors 0
Penelope A Morel
University of Pittsburgh
Career Start Year 1982
Number of shared co-authors 0
Anne M Dickinson
Translational and Clinical Research Institute, Newcastle University
Career Start Year 1981
Number of shared co-authors 1
David F Stroncek
Center for Cellular Engineering, NIH Clinical Center, National Institutes of Health
Career Start Year 1981
Number of shared co-authors 0
Robert E Lewis
University of Nebraska Medical Center
Career Start Year 1980
Number of shared co-authors 0
Elaine F Reed
University of California Los Angeles
Career Start Year 1980
Number of shared co-authors 0
Wolfgang Holter
St. Anna Children's Hospital, Medical University of Vienna
Career Start Year 1980
Number of shared co-authors 0
Peter S Linsley
8Benaroya Research Institute
Career Start Year 1978
Number of shared co-authors 0
Carl H June
University of Pennsylvania Department of Pathology & Laboratory Medicine
Career Start Year 1978
Number of shared co-authors 1
Victor H Engelhard
University of Virginia School of Medicine
Career Start Year 1976
Number of shared co-authors 0
Daniel W McVicar
National Cancer Institute
Career Start Year 1976
Number of shared co-authors 0
Gerald T Nepom
Wash Benaroya Research Institute at Virginia Mason
Career Start Year 1975
Number of shared co-authors 1
Hilary S Warren
Massachusetts General Hospital
Career Start Year 1973
Number of shared co-authors 0
Paola Ricciardi-Castagnoli
A. Menarini Biomarkers Singapore Pte Ltd
Career Start Year 1973
Number of shared co-authors 0
Ronald N Germain
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Career Start Year 1971
Number of shared co-authors 1
Giorgio Trinchieri
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1969
Number of shared co-authors 0
Shigeo Koyasu
RIKEN Center for Integrative Medical Sciences (IMS)
Career Start Year 1966
Number of shared co-authors 0
David W Scott
University of British Columbia
Career Start Year 1965
Number of shared co-authors 0

Collaborators

Dominique Charron
Universite de Strasbourg
Co-authored papers 40
Fawzi Aoudjit
CHU de Quebec Research Center
Co-authored papers 9
Catherine Alcaide-Loridan
Institute of Bioengineering, Miguel Hernandez University of Elche
Co-authored papers 8
Francisco Fern??ndez-Avil??s
Gregorio Maranon University Hospital
Co-authored papers 3
Isabelle Martins
Universite de Paris, Sorbonne Universite, Inserm U8, Institut Universitaire de France
Co-authored papers 3
Fr??d??rique Deshayes
Universite Paris Cite, CNRS
Co-authored papers 3
Khaoussou Sylla
Groupe Hospitalier Universitaire Paris Psychiatrie et Neurosciences
Co-authored papers 3
Philippe Menasché
Co-authored papers 2
Fabrice Baton
INSERM U
Co-authored papers 2
Rafick-Pierre Sekaly
Pathology Advanced Translational Research Unit, Emory University School of Medicine
Co-authored papers 1
Antoine Forget (CM4AI)
University of California San Francisco
Co-authored papers 1
Hélène Blons
Co-authored papers 1
Oliver Drews
Co-authored papers 1
Iwona A Ciechomska
Nencki Institute of Experimental Biology
Co-authored papers 1
Release 1.2